Skip to main content
. 2019 Jul 3;10:413. doi: 10.3389/fpsyt.2019.00413

Table 1.

Sociodemographic and clinical data: comparison between patients with poor and good insight.

Poor insight
(n = 124); BABS ≥ 14
Good insight
(n = 148); BABS = 0
Statistical test p
Median (Min–Max) Median (Min–Max)
Age 35.5 (13–68) 32 (10–77) UMW = 8,205.0 0.13
Studied years 14 (2–31) 14 (1–25) UMW = 8,412.0 0.27
n % n %
Male gender 52 41.9 72 48.6 X2 Yates = 0.97 0.33
No spouse 76 61.3 79 53.4 X2 Yates = 1.56 0.21
No occupation 27 18.2 23 18.5 X2 Yates < 0.01 1.00
Ethnicity: White 94 75.8 121 81.8 X2 Yates = 1.11 0.29
Socioeconomic Classification
Class A
Class B
Class C
Class D
Class E


8
54
48
11
3


6.5
43.5
38.7
8.9
2.4


26
58
54
7
3


17.6
39.2
36.5
4.7
2.0



X2 Pearson = 8.87



0.07
Current treatments
Pharmacological
—SSRIs
—Other antidepressants
—Benzodiazepines
—Mood stabilizers
—Lithium
—Neuroleptics

91
15
57
16
8
35

73.4
12.1
46.0
12.9
6.5
28.2

113
20
61
18
6
26

76.4
13.5
41.2
12.2
4.1
17.6

X2 Yates = 0.18
X2 Yates = 0.03
X2 Yates = 0.44
X2 Yates < 0.01
X2 Yates = 0.38
X2 Yates = 3.81

0.67
0.87
0.51
1.00
0.54
0.05
Any psychotherapy
CBT
73
20
58,9
27,4
96
25
64,9
26,0
X2 Yates = 0,79
X2 Yates = 0,02
0.37
0.90
Internment 15 12,1 8 5,4 X2 Yates = 0,47 0.49

p, level of statistical significance; n, absolute value; %, relative value; Min, minimum; Max, maximum; UMW, Mann–Whitney U test; χ2Yates, Yates chi-square test; χ2Pearson, Pearson chi-square test; SSRI, selective serotonin reuptake inhibitor; CBT, cognitive-behavioral therapy; BABS, Brown Belief Assessment Scale.

HHS Vulnerability Disclosure